You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Multi-Scale Simulation Framework for Heterogeneous Energetic Materials

    SBC: STREAMLINE NUMERICS, INC.            Topic: AF15AT28

    This Phase II STTR proposal will develop a computational tool for state-of-the-art computational modeling of multi-scale thermo-mechanics of heterogeneous energetic materials. The proposal will bring together researchers with long-standing expertise in flow software and physical modeling of high-speed reactive multi-material flows to work on further developing a cutting-edge computing tool called ...

    STTR Phase II 2017 Department of DefenseAir Force
  2. Receptors, Ligands, and Catalysts on Demand using Expanded Genetic Alphabets

    SBC: FIREBIRD BIOMOLECULAR SCIENCES LLC            Topic: 100

    ABSTRACTTechnology to deliveron demandmolecules that bind targets or catalyze reactions of choice has been a goal of chemistry foryearsEven todaytheory is inadequate to support de novo design of receptors having useful affinity or catalysts having useful turnoverThusmany have sought to create those catalysts on a DNA or RNAcollectivelyxNAusing the Darwinism to these biomolecules to evolveunder lab ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Prediction and Measurement of the Soot Build-Up in Film-Cooled Rocket Engines

    SBC: SIERRA ENGINEERING, INC.            Topic: AF15AT21

    This Phase II STTR effort is focused on generating the data necessary to identify the phenomenology that produces carbon deposition within kerosene film cooled rocket engines.This data is essential to guide the model development and validation process.Program outputs will be both data and a physics-based model for carbon deposition.

    STTR Phase II 2017 Department of DefenseAir Force
  4. Electrochemical Micro-Capacitors Utilizing Carbon Nanostructures

    SBC: MAINSTREAM ENGINEERING CORP            Topic: DMEA13B001

    The rapid advancement of microelectronics requires equivalently sized energy storage devices to provide energy for microelectromechanical system (MEMS) devices and other technologies. By using a novel approach to fabricate carbon nanotubes (CNTs), our electrodes have a high surface area with an aerial tube density up to 1,000 times greater than typical carpet-grown CNTs. By combining these electro ...

    STTR Phase II 2017 Department of DefenseAir Force
  5. Identification of Borrelia burgdorferi diagnostic biomarkers in humans and nonhum

    SBC: DXDISCOVERY INC            Topic: NIAID

    DESCRIPTION provided by applicant The number of Lyme disease cases in the US has been recently estimated by the CDC at cases year This is major public health concern Currently available diagnostics rely on detection of the antibody response serology to Borrelia burgdorferi the causative agent of Lyme disease However serological tests are not accurate during the early stages of Ly ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Identification of Small Molecule Amyloid Beta Peptide Reducing Agent

    SBC: Smart Biomolecules, Inc.            Topic: NIA

    Alzheimer s disease AD is a multifactorial heterogeneous and enormously complex disorder characterized by progressive intellectual deterioration Although remarkable advances have been made in unraveling the biological basis of the disease in the last two decades that immense knowledge has not been translated in to successful therapy With the failure of secretase inhibitors at the clinical tr ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Probabilistic Modeling for Software Guided Radiotherapy Patient Plan QA

    SBC: SUN NUCLEAR CORP.            Topic: 103

    Errors in the planning and delivery of radiation therapy can result in inferior outcomes for patients The magnitude of this problem is now well appreciated from cooperative group trials and other sources At present however there are few concrete tools to reduce the chance of plan errors passing undetected Current practice uses a variety of error mitigation means such as human inspection of th ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Therapeutic Neutralization of the Inflammasome After Spinal Cord Injury

    SBC: INFLAMACORE LIMITED LIABILITY COMPANY            Topic: NINDS

    PROJECT SUMMARY Spinal cord injury (SCI) is a complex and devastating clinical condition mediated by proinflammatory cytokines that produce neuronal loss, axonal destruction, and demyelination during the secondary injury cascade. There are currently no proven therapies targeting posttraumatic inflammation that have been shown to have clinical value. We have previously shown that central nervous sy ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Second generation MTI-101 analogs using a novel peptoid-peptide hybrid beta-hairp

    SBC: MODULATION THERAPEUTICS, INC.            Topic: NCI

    MTI-101 is a cyclic beta-hairpin peptide that binds CD44 with high affinity and kills multiple myeloma cell lines in vitro and blocks the growth of myeloma tumors in 2 different murine models. This interaction of MTI-101 with the surface of MM cells causesprogrammed cell necrosis, whereas all approved MM drugs cause apoptosis and so the novel mechanism of MTI-101 or MTI-like compounds makes it esp ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Galectin 1: A novel small protein therapy for Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: NIAMS

    DESCRIPTION provided by applicant Duchenne Muscular Dystrophy DMD is a fatal muscle disease affecting in every male births DMD results from mutations in the gene encoding the dystrophin a kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and a transmembrane protein complex called the dystrophin associated glycoprotein ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government